---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-085330"
form_type: "8-K"
ticker: "DFTX"
cik: "0001813814"
company_name: "Definium Therapeutics, Inc."
filed_at: "2022-03-25T23:59:59+00:00"
generated_at: "2026-06-26T17:36:03.570535+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# MindMed CFO David Guebert retiring Mar 31; director Vinson not seeking re-election; exec comp increases

## Summary
- CFO David Guebert's last day is March 31, 2022; search for new CFO launched with executive search firm.
- Director Sarah Y. Vinson will not stand for re-election at 2022 Annual Meeting; no disagreement cited.
- Board reduces size from 6 to 5 effective at 2022 Annual Meeting.
- CEO Robert Barrow base salary increased to $565,000, plus $233,411 cash bonus and equity awards.
- Executive President Miri Halperin Wernli base salary raised to $390,000 with 40% target bonus.

## SEC filing metadata
- accession: 0001193125-22-085330
- form_type: 8-K
- ticker: DFTX
- cik: 0001813814
- company_name: Definium Therapeutics, Inc.
- filed_at: 2022-03-25T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1813814/000119312522085330/0001193125-22-085330-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1813814/000119312522085330/d314752d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-085330
- JSON: https://secwatch.observer/filing/0001193125-22-085330.json
- Plain text: https://secwatch.observer/filing/0001193125-22-085330.txt

## Key facts
- Executive change
  David D. Guebert departed as Chief Financial Officer at Definium Therapeutics, Inc..
  - Action: separation from the Company
  - Role: Chief Financial Officer
  source text: On March 25, 2022, David D. Guebert and the Company agreed to a separation from the Company with Mr. Guebert’s last day of employment on March 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1813814/000119312522085330/0001193125-22-085330-index.htm
- Executive change
  Sarah Y. Vinson departed as Director at Definium Therapeutics, Inc..
  - Action: will not stand for re-election
  - Role: Director
  source text: On March 24, 2022, Sarah Y. Vinson, M.D. notified the Board of Directors (the “Board”) of Mind Medicine (MindMed) Inc. (the “Company”) that she will not stand for re-election as a director of the Company at its 2022 Annual Meeting
  evidence_url: https://www.sec.gov/Archives/edgar/data/1813814/000119312522085330/0001193125-22-085330-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.